Crowdberry launches new investment campaign for Slovak company whose technology enables early cancer detection

Glycanostics, a Slovak biotechnology company that has developed an innovative and accurate method for early cancer diagnosis, has launched a new investment campaign on the Crowdberry platform as part of a $10 million investment round. It plans to use the growth funds to develop and commercialize its revolutionary cancer diagnosis method, which is based on tracking changes in complex sugars on the surfaces of cells. Investor interest is proving to be considerable.  

Glycanostics' patented technology enables early and accurate diagnosis of various cancers from the blood, helping to improve treatment outcomes and save the lives of millions of patients by catching the disease in its early stages. Since the launch of the investment campaign on the Crowdberry platform, more than 100 investors have expressed interest in the €1.5 million fundraising. In addition to supporting a momentous product, the expected annual return in the tens of percent is also proving attractive to investors.

Cheaper blood test to replace invasive biopsies

Glycanostics has developed a unique blood test-based method of cancer diagnosis that analyses changes in complex sugars on the surfaces of cells. These sugars – technically glycans – change as the disease progresses, allowing Glycanostics to identify cancer with much higher accuracy than most methods available today, saving not only time but also money. This test has already been successfully used by Slovak urologists, preventing numerous, avoidable and especially traumatic procedures, which often unnecessarily drain public health spending. 

“We are currently providing the Giasay® Prostate diagnostic test to several urological outpatient clinics and we are also preparing a pharmacoeconomic study, which is an important prerequisite for the introduction of the test among the procedures covered by health insurance companies. However, this is only the beginning; the potential of the test is much broader than the field of prostate cancer. This field-proven test has the potential to detect 10 other types of cancer at an early stage and intensify cancer prevention. All it takes is a routine drawing of blood,